All Oncology News

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Pembrolizumab monotherapy and in combination with anlotinib demonstrated encouraging efficacy and safety when administered to patients with refractory or platinum-resistant recurrent high-grade serous ovarian cancer.

The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.

Indiana University School of Medicine has named Shelley Johns, PsyD, ABPP, the Walther Scholar in Psycho-Oncology.

The FDA has granted an orphan drug designation to AVA6000, a modified form of doxorubicin, for the treatment of patients with soft tissue sarcoma.

For clinicians tasked with treating patients with prostate cancer, disease visualization has traditionally consisted of imprecise techniques such as MRI. However, a new artificial intelligence-based approach by Avenda Health is poised to potentially revolutionize the treatment landscape in the field.

The FDA has granted an orphan drug designation to WP1122 as a potential therapeutic option for patients with glioblastoma multiforme.

The FDA has granted fast track designation to AMB-05X for the treatment of patients with tenosynovial giant cell tumors.

Toripalimab and concurrent chemoradiation elicited encouraging activity with acceptable tolerability in patients with locally advanced cervical cancer.

Naval G. Daver, MD, discusses the rationale for the ongoing ENHANCE trial and explained magrolimab’s unique role as a macrophage immune checkpoint blocker. He also outlines unmet needs throughout the entire high-risk myelodysplastic syndrome population, and how novel approaches, such as magrolimab combinations, may fulfill these needs.

Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.

More scientific evidence about the importance of nutrition and physical activity for cancer survivors has emerged in the past 10 years, prompting the American Cancer Society to update its guidance for physicians and patients.

Paul Bunn, MD, elaborates on carcinoembryonic antigen–related cell adhesion molecule 5 as a potential target in the treatment of non–small cell lung cancer.

The addition of the pre- and co-administration of nivolumab with concurrent chemoradiation appeared to be safe and feasible in patients with locally advanced cervical carcinoma, according to data from the phase 1 GOTIC-018 trial.

Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.

Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.

The FDA has approved the biosimilar pegfilgrastim for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

Florida Cancer Specialists & Research Institute announced the formation of additional precision oncology capabilities and resources comprised of geneticists, informatics specialists, and database technologies that will enhance patient care through comprehensive analysis of molecular data.

Immunotherapy in the form of ipilimumab plus nivolumab followed by the targeted therapy combination encorafenib plus binimetinib elicited an overall survival benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial.

A panel of hematology cancer experts discuss the current treatment landscape and novel emerging therapies for patients with myelofibrosis.

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Amputation is an independent predictor of poor outcomes among patients with high-grade bone sarcoma of lower extremity, and non-private insurance was found to be linked with increased likelihood of amputation and an advanced stage at presentation in this patient population.

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

DNA damage homologous recombination repair genotypic variants are not created equal.

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Fixed-duration bendamustine plus rituximab was effective in patients with previously untreated Waldenström macroglobulinemia, regardless of MYD88L265P mutation status, but the presence of the CXCR4WHIM mutation may be associated with resistance to the combination.

The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic biliary tract cancers.